Anti-Nerve growth factor [4D4 (Fulranumab; CNTO7309)], Mouse IgG2b, kappa

Absolute Antibody

Anti-Nerve growth factor [4D4 (Fulranumab; CNTO7309)], Mouse IgG2b, kappa

9

This antibody binds nerve growth factor (NGF). NGF is important for the development and maintenance of the sympathetic and sensory nervous systems. NGF is a neurotrophic factor that plays a key role in neuropathic and inflammatory-induced pain, promotes h

This antibody showed positive reactivity with human NGF in an ELISA. The original IgG antibody was reported to bind human NGF with a binding affinity of Kd= 4pM (US7601818). Upon administration, fulranumab binds to NGF, preventing its binding to and activation of the NGF receptors TrkA and p75NTR. Inhibition of the NGF pathway may prevent the perception of pain and may induce analgesia (NCI drug dictionary). A study examined the analgesic efficacy and safety of fulranumab in adults with chronic osteoarthritis pain found that fulranumab treatment resulted in statistically significant efficacy in pain measures and physical function versus placebo (PMID: 23748114). A phase I, randomized, placebo-controlled, double-blind study reported that AMG 403 was generally safe and well-tolerated in both healthy volunteers and knee osteoarthritis patients, and exhibited linear pharmacokinetics (PMID: 26449617).

ELISA

Research Use Only

Monoclonal

4D4 (Fulranumab; CNTO7309)

NGF

nerve growth factor

beta-nerve growth factor; Beta-NGF; HSAN5; nerve growth factor (beta polypeptide); nerve growth factor, beta subunit; NGFB; pro-nerve growth factor long

Mouse

IgG2b

Beta-nerve growth factor

Human

-20°C,2°C to 8°C

12352203